Pivotal Role of Akt Activation in Mitochondrial Protection and Cell Survival by Poly(ADP-ribose)polymerase-1 Inhibition in Oxidative Stress
Open accessThe DOI matches its Crossref record; 40 of the 58 references it cites were found in a registry or an index, and 18 are not checked yet.
Abstract
According to the classical view, the cytoprotective effect of inhibitors of poly(ADP-ribose)polymerase (PARP) in oxidative stress was based on the prevention of NAD+ and ATP depletion, thus the attenuation of necrosis. Our previous data on PARP inhibitors in an inflammatory model suggested that PARP-catalyzed ADP-ribosylations may affect signaling pathways, which can play a significant role in cell survival. To clarify the molecular mechanism of cytoprotection, PARP activity was inhibited pharmacologically by suppressing PARP-1 expression by a small interfering RNA (siRNA) technique or by transdominantly expressing the N-terminal DNA-binding domain of PARP-1 (PARP-DBD) in cultured cells. Cell survival, activation of the phosphatidylinositol 3-kinase (PI3-kinase)/Akt system, and the preservation of mitochondrial membrane potential were studied in hydrogen peroxide-treated WRL-68 cells. Our data showed that suppression of the single-stranded DNA break-induced PARP-1 activation by pharmacological inhibitor, siRNA, or by the transdominant expression of PARP-DBD protected cells from oxidative stress and induced the phosphorylation and activation of Akt. Furthermore, prevention of Akt activation by inhibiting PI3-kinase counteracted the cytoprotective effect of PARP inhibition. Microscopy data showed that PARP inhibition-induced Akt activation was responsible for protection of mitochondria in oxidative stress because PI3-kinase inhibitors diminished the protective effect of PARP in…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In our study, we observed that olaparib induces the activation of AKT, as a response to cellular stressors, aligning with findings from previous research [44].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [44]
Citations
Cites
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002) · Science · doi:10.1126/science.1072221 · Cited by 1,826
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
d'AMOURS, D., DESNOYERS, S., d'SILVA, I., & POIRIER, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,815
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia
Eliasson, M. J. L., Sampei, K., Mandir, A. S., Hurn, P. D., Traystman, R. J., Bao, J., Pieper, A., Wang, Z.-Q., Dawson, T. M., Snyder, S. H., et al. (1997) · Nature Medicine · doi:10.1038/nm1097-1089 · Cited by 1,018
Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion
Ha, H. C., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13978 · Cited by 907
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Poly(ADP-ribose) polymerase: a molecular nick-sensor
de Murcia, G., & de Murcia, J. M. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90280-1 · Cited by 797
Poly(ADP-Ribose) in the Cellular Response to DNA Damage
Berger, N. A. (1985) · Radiation Research · doi:10.2307/3576299 · Cited by 775
Research works printed but not linked: 7
- Turners, 1980, Biochem. J., 156, 434
- McCord, 1987, Fed. Proc., 46, 2402
- Palfi, 2005, J. Pharmacol. Exp. Ther.
- Wesierska-Gadek, 2001, Cell. Mol. Biol. Lett., 6, 117
- Amstad, 1992, Cancer Res., 52, 3952
- Powis, 1994, Cancer Res., 54, 2419
- Komjati, 2004, Int. J. Mol. Med., 13, 373
Cited by
Items 101–169 of 169
Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
Bonadio, R. C., & Estevez-Diz, M. D. P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754524 · Cited by 22
“org 3 and their upregulation may contribute to PARP resistance (29, 30).”
BackgroundRadnai, B., Antus, C., Rácz, B., Engelmann, P., Priber, J. K., Tucsek, Z., Veres, B., Turi, Z., Lóránd, T., Sümegi, B., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-34 · Cited by 21
“Activation of PARP and/or MAPKs could lead to mitochondrial depolarization [8,9,14].”
BackgroundSelf-citationYang, X., Wang, S., Lin, Y., Han, Y., Qiu, X., Zhao, X., Cao, L., Wang, X., & Chi, Z. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.009 · Cited by 21
“Recently, data showed that a PARP inhibitor could induce phosphorylation of Akt and GSK3b, responsible for the neuron protection in oxidative stress (Tapodi et al., 2005).”
InfluentialLee, Y. J., Lee, J., & Han, H. J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20763 · Cited by 21
“Cell proliferation, activation of the PI3K/Akt system, and the preservation of the mitochondrial membrane potential were examined in H2O2treated WRL-68 cells (Tapodi et al., 2005).”
BackgroundA Stronger DNA Damage-Induced G2 Checkpoint Due to Over-Activated CHK1 in the Absence of PARP-1
Lu, H., Wang, X., & Wang, Y. (2006) · Cell Cycle · doi:10.4161/cc.5.20.3355 · Cited by 22
Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma.
Szigeti, A., Minik, O., Hocsák, E., Pozsgai, É., Boronkai, Á., Farkas, R., Bálint, A. F., Bódis, J., Sümegi, B., & Bellyei, S. (2009) · PubMed · Cited by 21
Yuan, P., Ma, N., & Xu, B. (2024) · Medicinal Research Reviews · doi:10.1002/med.22058 · Cited by 23
The effect of GHRH antagonists on human glioblastomas and their mechanism of action
Pozsgai, É., Schally, A. V., Zarándi, M., Varga, J. L., Vidaurre, I., & Bellyei, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25259 · Cited by 20
“The integrity of the mitochondrial membrane system embodies a major factor against stress-induced damage.(20) To establish whether mitochondrial mechanisms are involved in the proapoptotic effect of GHRH antagonists, we stained DBTRG-05 cells that were treated with GHRH(1–29)NH2 or GHRH antagonists with the membrane p…”
BackgroundMethodFauzee, N. J. S., Qiao-zhuan, L., Wang, Y., & Pan, J. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9428-1 · Cited by 22
“that PARP-1 may be regulated by phosphorylation; meanwhile PARP-1 inhibition promoting Akt pathway has been outlined in these particular models [9–11].”
BackgroundNovel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer
McCann, K. E. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000428 · Cited by 19
Li, W. J., Shin, M.-K., & Oh, S. (2011) · Urology · doi:10.1016/j.urology.2011.01.022 · Cited by 19
Involvement of poly(ADP-ribose) polymerase in paraptotic cell death of D. discoideum
Rajawat, J., Mir, H., Alex, T., Bakshi, S. R., & Begum, R. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0920-9 · Cited by 18
“Cytoprotection by PARP inhibition is due to the prevention of NAD and ATP depletion caused by PARP overactivation [42].”
BackgroundZhang, L., Yao, J., Wang, X., Li, H., Liu, T., & Zhao, W. (2015) · PubMed · Cited by 18
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
Shao, N., Shi, Y., Yu, L., Ye, R., Shan, Z., Zhang, Z., Zhang, Y., & Lin, Y. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.30721 · Cited by 20
“Altered MET, PI3K/AKT pathways are involved in causing resistance to PARPi [119,120].”
BackgroundZhang, X., Huang, P., Wang, L., Chen, S., Basappa, B., Zhu, T., Lobie, P. E., & Pandey, V. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04982-8 · Cited by 18
Martín‐Guerrero, S. M., Muñoz‐Gámez, J. A., Carrasco, M., Salmerón, J., Martín‐Estebané, M., Cuadros, M. Á., Navascués, J., & Martín‐Oliva, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187130 · Cited by 17
Zhang, X., Wang, L., Chen, S., Huang, P., Ma, L., Ding, H., Basappa, B., Zhu, T., Lobie, P. E., & Pandey, V. (2022) · Communications Medicine · doi:10.1038/s43856-022-00142-3 · Cited by 17
“PARP inhibition in EOC cells has been reported to stimulate the activation of the RAS/MEK/ERK and PI3K/AKT/mTOR signaling pathways (2-5).”
BackgroundKalmar-Nagy, K., Degrell, P., Szabó, A., Sümegi, K., Wittmann, I., Gallyas, F., & Sümegi, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081928 · Cited by 18
“This activation may affect unfavorable signaling pathways (activation of JNK and p38 MAP kinase and suppression of Akt activation) that leads to cell death [34,46].”
BackgroundSelf-citationFarkas, R., Pozsgai, É., Bellyei, S., Cseke, L., Szigeti, A., Vereczkei, A. G., Marton, S., Mangel, L., Horváth, Ö. P., & Papp, A. (2011) · PubMed · Cited by 16
Gao, L., Kwan, J., Macdonald, P. S., Yang, L., Preiß, T., & Hicks, M. (2007) · Transplantation · doi:10.1097/01.tp.0000276924.08343.78 · Cited by 19
“While the initial rationale for pharmacological inhibition of PARP in the context of prevention of ischemia reperfusion injury was the prevention of the profound ATP and NAD depletion resulting from “hyperactivation” of PARP at reperfusion (25), recent studies have demonstrated that recruitment of the highly conserved…”
BackgroundWang, Y., Lin, X., Shi, C., Lŭ, L., Qin, Z., Zhu, G.-Z., Cao, X.-G., Ji, C., Qiu, J., & Guo, X. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9440-5 · Cited by 14
Li, W. J., Peng, Y., Zhou, J., Li, B., Wang, H., Zhang, J., & Wang, Z. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02666.x · Cited by 13
García, S., Mera, A., Gómez-Reino, J. J., & Conde, C. (2008) · Rheumatology · doi:10.1093/rheumatology/ken502 · Cited by 12
Hocsák, E., Rácz, B., Szabó, A., Pozsgai, É., Szigeti, A., Szigeti, E., Gallyas, F., Sümegi, B., Jávor, S., & Bellyei, S. (2010) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.06.010 · Cited by 11
Self-citationHuang, M., Chen, L., Ma, X., & Xu, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03542-8 · Cited by 9
“In our study, we observed that olaparib induces the activation of AKT, as a response to cellular stressors, aligning with findings from previous research [44].”
ResultYu, J., Zuo, T., Deng, W., Shi, Q., Ma, P., Chen, C., Zhao, L., Zhao, K., & Wang, W. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0493-5 · Cited by 9
Fioredda, F., Cappelli, E., Mariani, A., Beccaria, A., Palmisani, E., Grossi, A., Ceccherini, I., Venè, R., Micalizzi, C., Calvillo, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000575 · Cited by 9
“The absence of an immunomodulatory function of CASP8, enhanced by its lack of negative regulation by CASP10, interrupts the cleavage of CASP3, increases PARP pathway signaling, and causes hyperactivation of Akt–mammalian target of rapamycin.(16,17) According to the literature, mutations in either CASP8 or CASP10 (bein…”
BackgroundEvidence on Cholesterol-Controlled Lipid Raft Interaction of the Small Heat Shock Protein HSPB11
Török, Z., Pilbat, A., Gombos, I., Hocsák, E., Sümegi, B., Horváth, I., & Vígh, L. (2012) · Heat shock proteins · doi:10.1007/978-94-007-4740-1_5 · Cited by 9
Li, W. J., & Oh, S. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0588-y · Cited by 9
“On the other hand, recent studies have demonstrated that over-activation of PARP can inhibit the pro-survival Akt pathway, leading to cell death or apoptosis [22].”
BackgroundEnhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors
Yélamos, J., Galindo, M., Navarro, J., Albanell, J., Rovira, A., Rojo, F., & Oliver, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1065370 · Cited by 9
Zhi, W., Li, S., Wan, Y., Wu, F., & Li, H. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02447-8 · Cited by 9
“We performed in vivo and in vitro experiments and showed that STS synergistically enhanced the cytotoxicity of niraparib, including intensive double-strand DNA damage repair, inhibition of cell proliferation, apoptosis induction, cell cycle arrest and enhanced autophagic flux, and Akt/mTOR signalling was involved in t…”
Lovsund, T., Mashayekhi, F., Fitieh, A. M., Stafford, J. L., & Ismail, I. H. (2023) · Cells · doi:10.3390/cells12141904 · Cited by 8
Deng, O., Dash, S., Nepomuceno, T. C., Fang, B., Yun, S. Y., Welsh, E. A., Lawrence, H. R., Marchion, D. C., Koomen, J. M., Monteiro, Á. N. A., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102550 · Cited by 8
“Notably, PARP inhibition has also been reported to activate AKT resulting in cyto- and mitochondria protecting actions in oxidative stress [34].”
BackgroundRole of Mitochondrial Network Stabilisation by a Human Small Heat Shock Protein in Tumour Malignancy
Turi, Z., Hocsák, E., Rácz, B., Szabó, A., Balogh, A., Sümegi, B., & Gallyas, F. (2015) · Journal of Cancer · doi:10.7150/jca.11494 · Cited by 8
“The culture and harvesting of cells, isolation of cytosolic and mitochondrial fractions and immunoblotting were performed as previously described [9].”
MethodSelf-citationErős, K., Magyar, K., Deres, L., Skázel, Á., Riba, Á., Vámos, Z., Kálai, T., Gallyas, F., Sümegi, B., Tóth, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174401 · Cited by 9
Self-citationConstruction of PARPi Resistance-related Competing Endogenous RNA Network
Xiang, J., Kong, L., Xu, J., Yu, L., Liu, S., & Liu, Z. (2022) · Current Genomics · doi:10.2174/1389202923666220527114108 · Cited by 7
“The mechanisms of resistance to PARPi include PARP1 mutation, restoration of homologous recombination, BRCA1 promoter alterations, generation of hypomorphic BRCA proteins, decreased proteasomal degradation et al. [14] In addition, other mechanisms were involved in PARPirelated resistance, including PI3K/ATK pathway ac…”
BackgroundAmiodarone’s major metabolite, desethylamiodarone, induces apoptosis in human cervical cancer cells
Bognár, Z., Fekete, K., Bognar, R., Szabó, A., Vass, R. A., & Sümegi, B. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0113 · Cited by 7
PARP Activation and Necrotic Cell Death
Fan, Y., & Zong, W. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8220-8_9 · Cited by 5
Hiroki, H., Akahane, K., Inukai, T., Morio, T., & Takagi, M. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03520-8 · Cited by 5
“A potential unexpected effect of PARPi is PI3K/AKT pathway activation [14, 42], and phos-”
BackgroundTuo, L., Liu, Y., Zhu, H., Cao, L., Zhou, Y., Liu, D., & Shen, Q. (2024) · Biotechnology for Biofuels and Bioproducts · doi:10.1186/s13068-024-02502-8 · Cited by 4
“Besides, it is well documented that PARP inhibitors could protect against oxidative stress-induced cell death and prevent the oxidative stress-induced depolarization of MMP [30].”
BackgroundSynthesis of carotenoid-cysteine conjugates.
Zand, A., Agócs, A., Deli, J., & Nagy, V. (2012) · Acta Biochimica Polonica · doi:10.18388/abp.2012_2193 · Cited by 4
“The protective effect of the N-acetylcysteine derivatives were studied on WRL-68 type human liver cells in hydrogen-peroxide induced oxidative stress (Tapodi et al., 2005).”
BackgroundYan, J., LI, M.-C., Threadgill, M. D., Wang, Y., & Fu, W. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.44 · Cited by 4
Titterton, H. F., Bowen, C., & Khanbareh, H. (2025) · Advanced Materials Interfaces · doi:10.1002/admi.202500552 · Cited by 4
Hinchcliff, E., Westin, S. N., Molin, G. Z. D., Lafargue, C. J., & Coleman, R. L. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000499 · Cited by 3
Lee, S. J., & Lee, C. S. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0359-7 · Cited by 3
“Like ERK, the modulation of Akt activity reveals a different effect against the formation of ROS in prostate carcinoma cells (Poh and Pervaiz 2005) and against oxidative mitochondrial damage in cultured WRL-68 cells (Tapodi et al. 2005).”
BackgroundPoly(ADP-ribose) signal in seizures-induced neuron death
Chi, L., Wang, S., & Li, X. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.02.012 · Cited by 3
“It has been found to that PARP inhibition-induced Akt/glycogen synthase kinase-3b pathway is responsible for the neuron protection in oxidative stress and seizures [9,10].”
BackgroundIllés, Z., Lassmann, H., & Gallyas, F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7953-6_15 · Cited by 2
Self-citationDysfunction of the Bioenergetic Pathway
Singer, M. (2006) · Update in intensive care and emergency medicine · doi:10.1007/3-540-30328-6_21 · Cited by 2
“For example, in an oxidative stress model, PARP inhibition provided mitochondrial protection through inducing phosphorylation and activation of Akt [59].”
BackgroundCytoprotective Systems within the Kidney
Lash, L. H. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00805-8 · Cited by 2
Hou, X., Cai, C., He, Y., An, S., Zhao, S., Sun, H., & Yang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.799042 · Cited by 2
“Several works have proved that genetic and pharmaceutical disruption of PARP1 in oxidative stress played a protective role against cell death by maintaining integrity of mitochondrial membrane and activating phosphatidylinositol-3 kinase (PI3K)-AKT signal pathway (Veres et al., 2004; Tapodi et al., 2005; Bartha et al.…”
BackgroundHou, B., Huan, Z., Zhang, C., Chen, Z., Ha, L., & Huang, S.-X. (2022) · Folia Neuropathologica · doi:10.5114/fn.2022.114355 · Cited by 2
Chen, H., Guo, R., Zhang, C., Zhang, L., Hu, H., Du, P., Duan, J., Chen, L., Ma, X., Xue, J., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123820 · Cited by 1
Cytoprotective Systems Within the Kidneys☆
Lash, L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.02045-6 · Cited by 1
Translational Research on the Roles of Free Radicals and Antioxidants in Gastrointestinal Disorders
Szabó, I., Czimmer, J., & Mózsik, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_138 · Cited by 1
Rimel, B. J., Dockery, L., Randall, L. M., & Moore, K. N. (2020) · Future Oncology · doi:10.2217/fon-2020-0538 · Cited by 1
Current trends in chemotherapy for advanced ovarian cancer
Takahashi, N., & Takekuma, M. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac065 · Cited by 3
Hatano, E., Narita, M., & Üemoto, S. (2010) · Annals of Surgery · doi:10.1097/01.sla.0000369718.84750.6b · Cited by 1
Jeppesen, T. E. (2024) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/wtkq3953 · Cited by 1
“PARP enzymes, recognized for their critical role in DNA repair mechanisms, have been implicated in additional biological processes beyond cancers, such as managing oxidative stress, maintaining mitochondrial functionality, and regulating intermediary metabolism [14, 15].”
BackgroundLash, L. H. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_10
The role of PARP-1 induced AKT activation in cytostatic resistance
Szántó, Á. (2008) · Pesci Egyetemi Archivum (University of Pécs)
hepatocyteskinase signaling in primary cultured -induced necrosis by PKC and
Kaplowitz, N., Han, D., Saberi, B., Shinohara, M., Ybanez, M. D., Hanawa, N., & Gaarde, W. A. (2016)
Rôle des inhibiteurs de PARP dans le mimétisme vasculaire des cellules tumorales mammaires
Chivot, J. (2022) · theses.fr (ABES) · doi:10.70675/9446cc2az91aez4c0bzb0cczba1f18527ff3
Etude du microenvironnement tumoral des cancers de l’ovaire en fonction de l’instabilité génomique
Fumet, J.-D. (2022) · theses.fr (ABES) · doi:10.70675/ed5879b6z2c3az44f3z99cbz8466ad6dca12
Targeted therapy for BRCA gene mutations breast cancer
Basak, S., Singh, H., & Guru, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33349-1.00012-0
Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers
Lebeau, A., Kakkos, A., Leroi, N., Bours, V., Delbecque, K., Goffin, F., Gonne, E., & Gennigens, C. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251392106 · Cited by 1
“49 This resistance is due to secondary mutations restoring BRCA function, 50,51 activation of pro-survival signalling pathways (such as RAS and PI3K/AKT), 52,53 and stabilisation of replication forks.”
Li, T., Liu, Y., Zhu, H., Cao, L., Zhou, Y., Liu, D., & Shen, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26708753
Repurposing of PARP Inhibitors for the Clinical Management of Acute Cardiotoxicity
Gallyas, F., Halmosi, R., & Toth, K. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_37
Self-citation
Metadata
- Authors
- Tapodi, A., Debreceni, B., Hanto, K., Bognar, Z., Wittmann, I., Gallyas, F., Varbiro, G., & Sumegi, B.
- Affiliations
- University of Pecs (HU)
- ORCID
- Gallyas, Ferenc
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 280
- Issue
- 42
- Pages
- 35767-35775
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2075491707
- Cited by
- 166
- References
- 58
- Citations by year
- 2025: 5 · 2024: 5 · 2023: 3 · 2022: 10 · 2021: 6 · 2020: 11 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 6 · 2014: 8 · 2013: 10 · 2012: 14
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5480 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Keywords
- PARP1 inhibition, Akt activation, oxidative stress, mitochondrial protection, cell survival, PI3K signaling, mitochondrial membrane potential, hydrogen peroxide, single-strand breaks, ADP-ribosylation, Src kinase, cytoprotection, WRL-68 cells
- MeSH terms
- Acetylcysteine, Cell Line, Cell Survival, Enzyme Activation, Enzyme Inhibitors, Humans, Hydrogen Peroxide, Liver, Membrane Potentials, Microscopy, Fluorescence, Mitochondria, Models, Biological, Necrosis, Phosphorylation, Poly(ADP-ribose) Polymerases, Time Factors, Blotting, Western, Protein Structure, Tertiary, Oxidative Stress, Phosphatidylinositol 3-Kinases, RNA, Small Interfering, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.